EVO
Evotec SENASDAQHealthcare$2.59+1.97%ClosedMarket Cap: $920.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.00
P/S
1.06
EV/EBITDA
-11.82
DCF Value
$-3.98
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
10.8%
Operating Margin
-11.3%
Net Margin
-21.0%
ROE
-18.1%
ROA
-10.8%
ROIC
-5.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $163.9M | -0.0% | $-44.5M | $-43.1M | $-0.12 | — |
| Q2 2025 | $171.2M | 5.0% | $-27.8M | $-43.5M | $-0.12 | — |
| Q1 2025 | $200.0M | 13.6% | $-20.0M | $-31.6M | $-0.09 | — |
| Q4 2024 | $221.2M | 20.8% | $6.8M | $-40.8M | $-0.11 | — |
| FY 2024 | $797.0M | 14.4% | $-142.5M | $-196.1M | $-0.56 | — |
| Q3 2024 | $184.9M | 9.9% | $-26.5M | $-39.6M | $-0.11 | — |
| Q2 2024 | $182.1M | 8.6% | $-104.6M | $-94.9M | $-0.27 | — |
| Q1 2024 | $208.7M | 16.7% | $-18.2M | $-20.7M | $-0.06 | — |
| Q4 2023 | $201.3M | 18.7% | $-11.5M | $-16.1M | $-0.05 | — |
| FY 2023 | $781.4M | 22.4% | $-47.5M | $-83.9M | $-0.23 | — |
| Q3 2023 | $196.3M | 19.3% | $-12.2M | $-39.0M | $-0.11 | — |
| Q2 2023 | $170.3M | 27.2% | $-36.3M | $-14.9M | $-0.04 | — |